Articles | Volume 6, issue 1
https://doi.org/10.5194/jbji-6-17-2020
https://doi.org/10.5194/jbji-6-17-2020
Letter
 | 
22 Jul 2020
Letter |  | 22 Jul 2020

Comment on “Duration of rifampin therapy is a key determinant of improved outcomes in early-onset acute prosthetic joint infection due to Staphylococcus treated with a debridement, antibiotics and implant retention (DAIR): a retrospective multicenter study in France” by Becker et al. (2020)

Henk Scheper and Mark G. J. de Boer

Related authors

Wound drainage after arthroplasty and prediction of acute prosthetic joint infection: prospective data from a multicentre cohort study using a telemonitoring app
Henk Scheper, Rachid Mahdad, Brenda Elzer, Claudia Löwik, Wierd Zijlstra, Taco Gosens, Joris C. T. van der Lugt, Robert J. P. van der Wal, Rudolf W. Poolman, Matthijs P. Somford, Paul C. Jutte, Pieter K. Bos, Richard E. Zwaan, Rob G. H. H. Nelissen, Leo G. Visser, Mark G. J. de Boer, and the wound care app study group
J. Bone Joint Infect., 8, 59–70, https://doi.org/10.5194/jbji-8-59-2023,https://doi.org/10.5194/jbji-8-59-2023, 2023
Short summary

Cited articles

Becker, A., Kreitmann, L., Triffaut-Fillit, C., Valour, F., Mabrut, E., Forestier, E., Lesens, O., Cazorla, C., Descamps, S., Boyer, B., Chidiac, C., Lustig, S., Montbarbon, E., Batailler, C., and Ferry, T.: Duration of rifampin therapy is a key determinant of improved outcomes in early-onset acute prosthetic joint infection due to Staphylococcus treated with a debridement, antibiotics and implant retention (DAIR): a retrospective multicenter study in France, J. Bone Joint Infect., 5, 28–34, https://doi.org/10.7150/jbji.40333, 2020.